Journal article
Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology
Abstract
BackgroundIncremental cost-effectiveness ratios (ICERs) are used to assess the value for money of new drugs. Many believe that ICERs for drugs that treat rare diseases are much higher than those of common drugs. Our objective was to compare the proportion of ICERs that are cost effective for rare and common cancers.MethodsWe used the Tufts Medical Center Cost-Effectiveness Analysis (CEA) Registry to identify cost-effectiveness studies of …
Authors
Jayasundara K; Krahn M; Mamdani M; Hoch JS; Grootendorst P
Journal
PharmacoEconomics - Open, Vol. 1, No. 3, pp. 167–173
Publisher
Springer Nature
Publication Date
9 2017
DOI
10.1007/s41669-017-0022-7
ISSN
2509-4262